Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 54.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 610,606 shares of the company’s stock after selling 720,390 shares during the quarter. Hsbc Holdings PLC’s holdings in Teva Pharmaceutical Industries were worth $19,101,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of TEVA. Dorsey Wright & Associates purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $1,640,000. Compound Planning Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth $323,000. Invesco Ltd. lifted its position in Teva Pharmaceutical Industries by 4.8% in the fourth quarter. Invesco Ltd. now owns 2,710,105 shares of the company’s stock valued at $84,582,000 after acquiring an additional 124,304 shares during the last quarter. Corient Private Wealth LLC lifted its position in Teva Pharmaceutical Industries by 30.4% in the fourth quarter. Corient Private Wealth LLC now owns 49,848 shares of the company’s stock valued at $1,520,000 after acquiring an additional 11,628 shares during the last quarter. Finally, Alpine Woods Capital Investors LLC acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at $463,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Activity

In related news, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the transaction, the executive vice president owned 63,647 shares of the company’s stock, valued at $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares in the company, valued at $2,825,792.40. This trade represents a 64.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 465,931 shares of company stock valued at $16,332,989. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 3.0%

Shares of NYSE:TEVA opened at $34.20 on Thursday. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The stock has a market cap of $39.33 billion, a P/E ratio of 25.72, a P/E/G ratio of 3.74 and a beta of 0.84. The firm has a fifty day moving average price of $33.66 and a 200 day moving average price of $32.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion for the quarter. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.14 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on TEVA. Piper Sandler reaffirmed an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. UBS Group boosted their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Bank of America upped their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Finally, Barclays lifted their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.